{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:15:46Z","timestamp":1769094946994,"version":"3.49.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neur Clin Pract"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1212\/cpj.0b013e31825a77ca","type":"journal-article","created":{"date-parts":[[2012,6,11]],"date-time":"2012-06-11T20:26:15Z","timestamp":1339446375000},"page":"134-138","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["An analysis of AAN\u2032s evidence-based guideline for IVIg use in neurologic disorders"],"prefix":"10.1212","volume":"2","author":[{"given":"Saty","family":"Satya-Murti","sequence":"first","affiliation":[{"name":"Health Policy Consultant (SS-M), Santa Maria, CA; American Academy of Neurology (KMS), Minneapolis, MN; and Department of Neurology (JMK), Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie M.","family":"Shepard","sequence":"additional","affiliation":[{"name":"Health Policy Consultant (SS-M), Santa Maria, CA; American Academy of Neurology (KMS), Minneapolis, MN; and Department of Neurology (JMK), Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Health Policy Consultant (SS-M), Santa Maria, CA; American Academy of Neurology (KMS), Minneapolis, MN; and Department of Neurology (JMK), Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824de293"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2011.1960","article-title":"Reversals of established medical practices: evidence to abandon ship","volume":"307","author":"Prasad V","year":"2012","unstructured":"Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. JAMA 2012;307:37\u201338.","journal-title":"JAMA"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1478-7547-8-14","article-title":"Cost-utility of intravenous immunoglobulin (IGIV) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada","volume":"8","author":"Blackhouse G","year":"2010","unstructured":"Blackhouse G, Gaebel K, Xie F, et al.. Cost-utility of intravenous immunoglobulin (IGIV) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010;8:14.","journal-title":"Cost Eff Resour Alloc"},{"key":"e_1_3_1_5_2","unstructured":"Medicare Coverage Database CMS Centers for Medicare & Medicaid Services. Available at: https:\/\/www.cms.gov\/medicare-coverage-database. Accessed February 7 2012."},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.41.5.617","article-title":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"41","author":"Cornblath DR","year":"1991","unstructured":"Cornblath DR, Feasby TE, Hahn AF, et al.. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617\u2013618.","journal-title":"Neurology"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2010.00245.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2013First Revision","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","unstructured":"Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2013First Revision. J Peripher Nerv Syst 2010;15:1\u20139.","journal-title":"J Peripher Nerv Syst"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.294.6.741","article-title":"Adding value to evidence-based clinical guidelines","volume":"294","author":"O'Connor PJ","year":"2005","unstructured":"O'Connor PJ. Adding value to evidence-based clinical guidelines. JAMA 2005;294:741\u2013743.","journal-title":"JAMA"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2753.2009.01209.x","article-title":"Balancing health care evidence and art to meet clinical needs: policymakers' perspectives","volume":"15","author":"Parker LE","year":"2009","unstructured":"Parker LE, Ritchie MJ, Kirchner JE, Owen RR. Balancing health care evidence and art to meet clinical needs: policymakers' perspectives. J Eval Clin Pract 2009;15:970\u2013975.","journal-title":"J Eval Clin Pract"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"e21704","DOI":"10.1371\/journal.pone.0021704","article-title":"The use of research evidence in public health decision making processes: systematic review","volume":"6","author":"Orton L","year":"2011","unstructured":"Orton L, Lloyd-Williams F, Taylor-Robinson D, O'Flaherty M, Capewell S. The use of research evidence in public health decision making processes: systematic review. PLoS One 2011;6:e21704.","journal-title":"PLoS One"}],"container-title":["Neurology Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/CPJ.0b013e31825a77ca","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T16:46:58Z","timestamp":1711558018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/CPJ.0b013e31825a77ca"}},"subtitle":["Provider impact and payer perspectives"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1212\/CPJ.0b013e31825a77ca"],"URL":"https:\/\/doi.org\/10.1212\/cpj.0b013e31825a77ca","relation":{},"ISSN":["2163-0402","2163-0933"],"issn-type":[{"value":"2163-0402","type":"print"},{"value":"2163-0933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}